FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
MLND Financial Statements
Year
2020
2019
2018
2017
Current Assets
40.9M
71.13M
83.42M
68.78M
Cash & Short Term Investments
38.17M
62.48M
77.67M
67.2M
Cash And Cash Equivalents
38.17M
62.48M
73.29M
15.7M
Short Term Investments
0
0
4.38M
51.5M
Net Receivables
314k
1.28M
2.33M
0
Inventory
0
0
0
0
Other Current Assets
2.41M
7.38M
3.42M
1.58M
Non-Current Assets
2.51M
3.84M
652k
4.07M
Property, Plant & Equipment
2.16M
3.33M
0
3.11M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
146k
Tax Assets
0
0
0
0
Other Non-Current Assets
351k
507k
652k
813k
Other Assets
0
0
0
0
Total Assets
43.41M
74.97M
84.07M
72.85M
-
-
-
-
Current Liabilities
7.99M
12.52M
9.82M
7.8M
Accounts Payable
1.49M
1.5M
2M
2.24M
Short Term Debt
976k
1.96M
189k
0
Tax Payables
0
0
0
0
Deferred Revenue
0
0
0
334k
Other Current Liabilities
5.53M
9.07M
7.63M
5.23M
Total Current Liabilities
7.99M
12.52M
9.82M
7.8M
Total Non-Current Liabilities
1.7M
2.58M
1.14M
751k
Long-Term Debt
1.7M
2.56M
383k
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
0
16k
752k
751k
Total Liabilities
9.68M
15.1M
10.95M
8.55M
Other Liabilities
0
0
0
0
Stockholders Equity
33.73M
59.87M
73.12M
64.3M
Common Stock
19k
18k
13k
36k
Retained Earnings
-245.06M
-208.65M
-164.09M
-301.48M
Accumulated Other Comprehensive Income/Loss
452k
165k
148k
-27k
Other Shareholders Equity
278.31M
268.34M
237.05M
365.77M
Total Liabilities and Stockholders Equity
43.41M
74.97M
84.07M
72.85M
Retained Earning Schedule
Year
2020
2019
2018
2017
Retained Earnings (Previous Year)
-208.65M
-164.09M
-301.48M
-250.18M
Net Income
-36.41M
-44.57M
-27.19M
-50.98M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-245.06M
-208.65M
-164.09M
-301.48M
Other Distributions
-36.41M
-44.57M
137.39M
-51.3M
PPE Schedule
Year
2020
2019
2018
2017
Gross PPE
2.16M
3.33M
0
3.11M
Annual Depreciation
1.1M
1.05M
32k
1.65M
Capital Expenditure
-26k
-397k
-36k
-158k
Net PPE
1.08M
2.68M
4k
1.62M
Intangible and Goodwill Schedule
Year
2020
2019
2018
2017
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
